English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60008
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Cyclin D3 gene amplification in bladder carcinoma in situ

AuthorsLópez-Beltran, A.; Ordóñez, José Luis ; Otero, Ana P.; Sevillano, Victoria ; Álava, Enrique de
Issue Date2010
PublisherSpringer
CitationVirchows Archiv 457(5): 555-561 (2010)
AbstractCarcinoma in situ (CIS) is a non-papillary high-grade, potentially aggressive, and unpredictable manifestation of bladder urothelial carcinoma. The aim of this study was to assess patterns of Cyclin D3 gene amplification in Bacillus Calmette-Guerin (BCG)-treated CIS and correlate gene status with recurrence-free and progression-free survival. A sequential cohort series of 28 primary (isolated) or secondary (concomitant) bladder CIS samples in which there was enough tissue material to assess Cyclin D3 gene status by fluorescent in situ hybridization was the study group. Cyclin D3 gene amplification was present in 29% of secondary CIS; none of primary CIS samples had Cyclin D3 gene amplification. Cyclin D3 amplification was related to recurrence- (p=0.046) and progression-free survival (p=0.002). Type of bladder CIS (primary vs. secondary) was unrelated to recurrence- or progression-free survival in the current series. Cox's regression analysis selected Cyclin D3 as an independent predictor of progression-free survival (p=0.041, relative risk=61.503, 95% confidence interval=1.1-274.710). None of primary CIS cases recurred on follow-up; nine secondary CIS recurred and four of them progressed to invasive bladder carcinoma HG T1 (n=1), T2b N0M0 (n=1), T3b N1M0 (n=1) and T4aN1M1 (n=1). Mean recurrence±SD (months) occurred at 19.5±2.06 (95% (confidence interval (CI)), 15.5-23.6); mean progression (months) occurred at 23.8±1.46 (95% (CI), 20.9-26.7). Our study suggests that Cyclin D3 gene amplification might be a predictor of aggressiveness in BCG-treated CIS. © 2010 Springer-Verlag.
URIhttp://hdl.handle.net/10261/60008
DOI10.1007/s00428-010-0969-6
Identifiersdoi: 10.1007/s00428-010-0969-6
issn: 0945-6317
e-issn: 1432-2307
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.